Alliance Pharma PLC Notification of Half Year Results (7459K)
September 06 2021 - 1:00AM
UK Regulatory
TIDMAPH
RNS Number : 7459K
Alliance Pharma PLC
06 September 2021
For immediate release 6 September 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Notification of Half Year Results,
Results Presentation and Analyst Call
Alliance Pharma plc (AIM: APH), the international healthcare
group, will announce its results for the six months ended 30 June
2021 on Tuesday 21 September 2021.
A link to a recorded presentation of the half year results, by
Peter Butterfield, Chief Executive Officer, and Andrew Franklin,
Chief Financial Officer, will be included in the results
announcement.
The recorded presentation will also be made available at the
investor section of Alliance's website,
https://www.alliancepharmaceuticals.com/investors/ .
A Q&A call for analysts will be held at 10.00am on the day
of the results, 21 September 2021; analysts who require joining
details should contact Buchanan at alliancepharma@buchanan.uk.com
.
For any further information, please contact Buchanan at the
details below.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Duncan Monteith
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group. Our purpose is to improve the lives of consumers and
patients through making available a range of clinically valuable
healthcare products.
Our core focus is on the marketing of Consumer Healthcare
brands, complemented by a smaller Prescription Medicines business.
In total, we hold marketing rights to around 80 brands, with
revenues generated from a mix of direct, distributor and e-commerce
sales.
Headquartered in the UK, the Group employs around 250 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics
operations, we remain asset-light and focused on maximising the
value of our brands.
More information on Alliance can be found on our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSSFMDEFSEDU
(END) Dow Jones Newswires
September 06, 2021 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024